SEPROGADIC-serum protein-based gastric cancer prediction model for prognosis and selection of proper adjuvant therapy

Authors
Ahn, Hee-SungSohn, Tae SungKim, Mi JeongCho, Byoung KyuKim, Su MiKim, Seung TaeYi, Eugene C.Lee, Cheolju
Issue Date
2018-11-15
Publisher
NATURE PUBLISHING GROUP
Citation
SCIENTIFIC REPORTS, v.8
Abstract
Gastric cancer (GC) patients usually receive surgical treatment. Postoperative therapeutic options such as anticancer adjuvant therapies (AT) based on prognostic prediction models would provide patient-specific treatment to decrease postsurgical morbidity and mortality rates. Relevant prognostic factors in resected GC patient's serum may improve therapeutic measures in a non-invasive manner. In order to develop a GC prognostic model, we designed a retrospective study. In this study, serum samples were collected from 227 patients at a 4-week recovery period after D2 lymph node dissection, and 103 cancer-related serum proteins were analyzed by multiple reaction monitoring mass spectrometry. Using the quantitative values of the serum proteins, we developed SEPROGADIC (SErum PROtein-based GAstric cancer preDICtor) prognostic model consisting of 6 to 14 serum proteins depending on detailed purposes of the model, prognosis prediction and proper AT selection. SEPROGADIC could clearly classify patients with good or bad prognosis at each TNM stage (113, 2, 3 and 4) and identify a patient subgroup who would benefit from CCRT (combined chemoradiation therapy) rather than CTX (chemotherapy), or vice versa. Our study demonstrated that serum proteins could serve as prognostic factors along with clinical stage information in patients with resected gastric cancer, thus allowing patient-tailored postsurgical treatment.
Keywords
LYMPH-NODE DISSECTION; PLASMA-PROTEOME; COMPANION DIAGNOSTICS; BIOMARKER DISCOVERY; RADIATION-THERAPY; MASS-SPECTROMETRY; ROC CURVES; EXPRESSION; TRIAL; CHEMOTHERAPY; LYMPH-NODE DISSECTION; PLASMA-PROTEOME; COMPANION DIAGNOSTICS; BIOMARKER DISCOVERY; RADIATION-THERAPY; MASS-SPECTROMETRY; ROC CURVES; EXPRESSION; TRIAL; CHEMOTHERAPY
ISSN
2045-2322
URI
https://pubs.kist.re.kr/handle/201004/120676
DOI
10.1038/s41598-018-34858-x
Appears in Collections:
KIST Article > 2018
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE